PHARMARON UK LIMITED
Get an alert when PHARMARON UK LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£19M
+34.9% highest in 3 filed years
Net assets
£181M
-7.3% vs 2024
Employees
697
+1.9% highest in 3 filed years
Profit before tax
-£15M
-199.7% lowest in 3 filed years
Net assets
3-year trend · vs Health Care median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £125,445,000 | £114,155,000 | £116,563,000 | +2.1% | |
| Operating profit | £7,140,000 | -£5,136,000 | -£16,042,000 | -212.3% | |
| Profit before tax | £7,324,000 | -£5,023,000 | -£15,053,000 | -199.7% | |
| Net profit | £6,092,000 | -£6,479,000 | -£15,053,000 | -132.3% | |
| Cash | £15,494,000 | £14,147,000 | £19,078,000 | +34.9% | |
| Total assets less current liabilities | £207,416,000 | £232,526,000 | — | — | |
| Net assets | £152,597,000 | £195,350,000 | £181,023,000 | -7.3% | |
| Equity | £152,597,000 | £195,350,000 | £181,023,000 | -7.3% | |
| Average employees | 631 | 684 | 697 | +1.9% | |
| Wages | £36,550,000 | £40,272,000 | £39,585,000 | -1.7% | |
| Directors' remuneration | £378,000 | £254,000 | £277,000 | +9.1% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Operating margin | 5.7% | -4.5% | -13.8% | |
| Net margin | 4.9% | -5.7% | -12.9% | |
| Return on capital employed | 3.4% | -2.2% | — | |
| Gearing (liabilities / total assets) | 41.5% | 30.6% | 26.6% | |
| Current ratio | 0.99x | 2.72x | 1.07x | |
| Interest cover | 3.25x | -1.83x | -71.94x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 2 times since incorporation
- PHARMARON UK LIMITED 2016-09-01 → present
- QUOTIENT BIORESEARCH GROUP LIMITED 2014-04-11 → 2016-09-01
- QBRG LIMITED 2013-10-30 → 2014-04-11
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Standalone (parent only)
- Auditor
- Azets Audit Services
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issu”
Group structure
- PHARMARON UK LIMITED · parent
- Quotient Bioresearch (Radiochemicals) United Kingdom Non-trading Limited 100%
Significant events
- “As part of a group restructure, the investment in the subsidiary company Pharmaron Manufacturing Services (UK) Limited was sold for book value on 2 January 2025. The purchaser was the immediate parent company of Pharmaron UK Limited, Pharmaron (Hong Kong) International Limited.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 8 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| LEWINTON, Stephen Christopher | Secretary | 2016-02-02 | — | — |
| LEWINTON, Stephen Christopher, Mr. | Director | 2022-11-04 | Apr 1966 | British |
| LOU, Boliang, Dr | Director | 2016-02-02 | Sep 1963 | American |
Show 8 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BURDETT, Roger Leonard | Director | 2013-10-30 | 2016-02-02 |
| CAMERON, Gordon | Director | 2013-10-30 | 2016-02-02 |
| CARTER, Mark | Director | 2013-12-10 | 2016-02-02 |
| EGERTON, Mark, Dr. | Director | 2013-12-10 | 2016-02-02 |
| GOLDSTEIN, Jonathan | Director | 2013-12-10 | 2016-02-02 |
| HEMMINGS, Simon Robert | Director | 2015-01-05 | 2016-02-02 |
| LEWINTON, Stephen Christopher, Mr. | Director | 2013-12-10 | 2016-03-23 |
| PLEASANCE, Stephen, Dr | Director | 2013-12-10 | 2016-02-02 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Dr. Boliang Lou | Individual | Shares 75–100%, Voting 75–100%, Appoints directors | 2020-12-02 | Active |
| Xiaoqiang Lou | Individual | Shares 75–100%, Voting 75–100%, Appoints directors | 2020-12-02 | Active |
| Bei Zheng | Individual | Shares 75–100%, Voting 75–100%, Appoints directors | 2020-12-02 | Active |
| Mr Boliang Lou | Individual | Appoints directors | 2016-04-06 | Ceased 2022-11-04 |
Filing timeline
Last 20 of 94 total filings
Material constitutional events — rename, articles re-file, resolution
- 2024-04-07 RESOLUTIONS Resolution
- 2024-04-07 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-06-06 | AA | accounts | Accounts with accounts type full | |
| 2026-04-24 | SH01 | capital | Capital allotment shares | |
| 2025-12-16 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-10-02 | PSC04 | persons-with-significant-control | Change to a person with significant control | |
| 2025-10-02 | PSC04 | persons-with-significant-control | Change to a person with significant control | |
| 2025-07-29 | PSC01 | persons-with-significant-control | Notification of a person with significant control | |
| 2025-07-29 | PSC01 | persons-with-significant-control | Notification of a person with significant control | |
| 2025-07-28 | PSC01 | persons-with-significant-control | Notification of a person with significant control | |
| 2025-07-28 | PSC09 | persons-with-significant-control | Withdrawal of a person with significant control statement | |
| 2025-05-08 | AA | accounts | Accounts with accounts type full | |
| 2024-12-20 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-08-12 | SH01 | capital | Capital allotment shares | |
| 2024-07-08 | AA | accounts | Accounts with accounts type full | |
| 2024-04-07 | RESOLUTIONS | resolution | Resolution | |
| 2024-04-07 | RESOLUTIONS | resolution | Resolution | |
| 2024-04-03 | SH01 | capital | Capital allotment shares | |
| 2023-12-14 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-08-30 | AA | accounts | Accounts with accounts type full | |
| 2022-12-23 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2022-12-23 | AD02 | address | Change sail address company with old address new address |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 9
- Capital events
- 2
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.